Therapeutics and Clinical Risk Management

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications" in Therapeutics and Clinical Risk Management.

Lymphoproliferation, clinically expressed with lymphadenopathies, hepato-splenomegaly, or lymphoid organ infiltration, is a common feature of different diseases, ranging from infections to hematologic malignancies. In the recent years, there has also been an increasing interest in the impact of lymphoproliferative features in patients with inborn errors of immunity (IEI), as benign polyclonal lymphoproliferation is one of the leading signs in different IEIs, including the autoimmune lymphoproliferative syndrome and other immune dysregulation disorders. Moreover, the knowledge on lymphoproliferative malignancies israpidly progressing, with the increasing availability of new therapeutic regimens.

Therefore, a deeper understanding of the diseases featured by lymphoproliferation is warranted, in order to improve the recognition and treatment of the main causes of lymphoproliferation, including IEIs and malignancies.

This aim of this Article Collection is to offer an overview of lymphoproliferative diseases, considering the diagnostic aspect (with a specific focus on the new diseases associated with lymphoproliferation) and the therapeutic options in the setting of both polyclonal and malignant lymphoproliferation. Specifically, the possibility to have the contribution from both an immunological and onco-hematological point of view could significantly increase the impact of this Collection. This Article Collection will consider review papers and original research papers.

Keywords

• Lymphadenopathy
• Inborn errors of immunity
• Immune dysregulation
• Lymphomas
• Splenomegaly

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 November 2024.

Please submit your manuscript on our website, quoting the promo code IHLGQ to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Giorgio Costagliola, Azienda Ospedaliero Universitaria Pisana (AOUP)

[email protected]

Medical doctor and researcher at the Pediatric Hematology and Oncology Department of the Azienda Ospedaliero Unviersitaria Pisana (AOUP), with a special focus on inborn errors of immunity. Junior member of the European Society for Immunodeficiencies and member of the Associazione Italiana Oncologia ed Ematologia Pediatrica (AIEOP) and Italian Primary Immunodeficiency network (IPINET).

Rita Consolini, University of Pisa

[email protected]

Professor of Pediatrics at the University of Pisa, involved in teaching pediatric and immunology. Medical Doctor 1976 University of Pisa, Italy (pass with distinction). Expertise in Pediatrics (1979), Immunology (1982) and Haematology (1986). Member European Society for Immunodeficiencies (ESID), Associazione Italiana Oncologia ed Ematologia Pediatrica (AIEOP) and Italian Primary Immunodeficiency network (IPINET).

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Unlocking the Secrets of the Nervous System: Unveiling the Biomarkers of Neurological Diseases" in Therapeutics and Clinical Risk Management.

This Collection aims to compile groundbreaking research and insights into the biomarkers associated with neurological diseases. Biomarkers play a crucial role in understanding the pathophysiology of neurological disorders, aiding in early diagnosis, prognosis prediction, and monitoring the efficacy of therapeutic interventions. The gathered articles will explore the diverse range of biomarkers, from genetic and protein markers to imaging and clinical biomarkers, that are instrumental in unravelling the complexities of neurological diseases.

The importance of identifying and understanding biomarkers in neurological diseases cannot be overstated. These markers provide valuable information about the disease process, ultimately facilitating personalized medicine approaches and more effective treatments. By elucidating the intricate relationship between biomarkers and neurological diseases, we can unlock new avenues for research and intervention, thereby improving patient outcomes and contributing to the global fight against these debilitating conditions.

We invite authors to submit original research articles, comprehensive reviews, and perspective pieces that delve into the various aspects of biomarkers in neurological diseases. Submissions should focus on topics such as the identification and validation of new biomarkers, the role of biomarkers in disease progression and treatment response, and the challenges and opportunities in translating biomarker research into clinical practice. Through this article collection, we aim to create a valuable resource for researchers, clinicians, and anyone with an interest in the dynamic field of neurological diseases and their associated biomarkers.

Keywords

• Neurological Diseases
• Biomarkers
• Prognosis
• Disease Monitoring
• Clinical Applications

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 December 2024.

Please submit your manuscript on our website, quoting the promo code RFPYX to indicate that your submission is for consideration in this Article Collection.

Guest Advisor

Xiaoqiao Dong, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

[email protected]

Dr. Xiaoqiao Dong holds a doctoral degree and is a chief physician and master's degree supervisor. He specializes in clinical work related to traumatic brain injuries, spontaneous cerebral hemorrhage, and subarachnoid hemorrhage, and conducts basic and clinical research on acute brain injuries. Dr. Dong has participated in more than 30 projects, published over 70 SCI articles, received 9 awards for scientific and technological progress, and obtained 3 invention patents.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Machine Learning in the Realm of Therapeutics and Clinical Risk Management" in Therapeutics and Clinical Risk Management.

Machine Learning (ML) and healthcare is one of the most interesting research topics in modern medicine, giving the opportunity to improve patient care, diagnosis, personalized treatment and risk management. The fast evolving of data analytics can improve the vast amount of health data analysis, aiming to improve outcomes, reduce costs and personalize healthcare. Giving the increasing use of healthcare systems that face aging populations, chronic disease and cost effective treatments, ML integration offers a hope, driving innovations of clinical care, research, and public health.

The integration of machine learning (ML) in medicine revolutionizes healthcare by improving diagnostic accuracy, treatment personalization, risk management, and research. ML algorithms analyse large clinical datasets, identifying precise patterns and correlations for enhanced disease detection and understanding. Personalized treatment recommendations are made by analysing individual patient features, optimizing efficacy while minimizing adverse effects. ML’s predictive capabilities enable proactive risk management, predicting disease development and complications to preventive strategies. Additionally, ML drives rigorous medical research by identifying new associations and generating hypotheses from massive datasets.

This Collection seeks to explore the impact of ML in healthcare, with contributions that explore the advancements, applications, analysis and case studies of ML in healthcare. We welcome submissions of original clinical research, but not limited to, ML’s role in diagnostics, personalized medicine, preventive healthcare, data in healthcare, clinical practices and technologies. Through this collection, we aim to encapsulate the current state, future directions, and broader implications of Machine Learning in the realm of Therapeutics and Clinical Risk Management.

Keywords

• Machine Learning
• Healthcare Innovation
• Personalized Medicine
• Clinical Risk with Machine Learning
• Clinical Data Mining

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code VZRCQ to indicate that your submission is for consideration in this Article Collection.

Please note that any paper submitted is subject to the standard Article Processing Charge. Contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

The deadline for submitting manuscripts is 31 December 2024. 

Guest Advisors

Carlos Eric Galván-Tejada, Autonomous University of Zacatecas, Mexico

[email protected]

PhD. Carlos Eric Galván Tejada has excelled in merging computing with biomedicine, focusing on bioinformatics and clinical data analysis to develop non-invasive diagnostic tools for complex diseases using artificial intelligence and data science. His work has significantly advanced digital medicine and health, making notable contributions to the field through research, scientific dissemination, and collaborative projects. Galván Tejada has promoted interest in science among students and young people, emphasizing technology's role in medical practice evolution. His efforts have gained international academic recognition, evidenced by high-impact publications and active participation in health care innovation forums. Committed to education and research, he is a member of the National System of Researchers in Medicine and Health Sciences, continually pushing the boundaries of knowledge in biomedicine and medical technology.

José M. Celaya-Padilla, Autonomous University of Zacatecas, Mexico

[email protected]

Acknowledgement: Valeria Maeda Gutiérrez, PhD, [email protected], Autonomous University of Zacatecas, Mexico. She would take on additional tasks and responsibilities for the Article Collection, similar to those of an advisor.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome" in Therapeutics and Clinical Risk Management.

Cardio-Kidney-Metabolic (CKM) syndrome has been recently recognized by the American Heart Association (AHA) as the close interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic risk factors, mainly diabetes mellitus and obesity. CKM syndrome has attracted scientific attention due to its growing prevalence worldwide, reaching pandemic dimensions, whereas, several newer and novel therapeutic agents, targeting various pathophysiological aspects of CKM syndrome, have emerged over the last years, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, incretin-based agents, tirzepatide, finerenone, and many other. The aim of this Article Collection is to gather scientific evidence regarding the impact of newer therapeutic agents on various components of CKM syndrome, as adjunct to established treatment options.

According to recent evidence from the United States, approximately 90% of the U.S. population appear to be at some stage of CKM syndrome. In addition, CVD still represents one of the leading causes of death worldwide, whereas it is also associated with substantial morbidity and healthcare costs. Based on evidence from the European Union, in 2021, more than 280 billion euros were spent for the therapeutic management of patients with some form of CVD, which was the leading cause of death, followed by cancer. Since there is an increasing prevalence of dysmetabolism, including diabetes mellitus and obesity, it is of utmost importance to early identify specific patients’ phenotypes and apply appropriate therapeutic strategies against the progression of CKM syndrome, to minimize relevant morbidity and of course mortality.

Sub-topics of specific interest

• Older antidiabetic drug classes and CKM syndrome
• SGLT-2 inhibitors and CKM syndrome
• Incretin-based agents and CKM syndrome
• Novel anti-obesity drugs and cardio-renal implications
• RAAS blockers and CKM syndrome
• Implications of artificial intelligence as a therapeutic tool in CKM syndrome
• Novel technologies in the therapeutic management of patients with CKM syndrome

Preferred article types

• Original articles
• Systematic reviews and/or meta-analyses
• Narrative reviews

Keywords

• Cardiovascular disease
• Chronic kidney disease
• Diabetes mellitus
• Obesity
• Therapeutics

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code ZDHVP to indicate that your submission is for consideration in this Article Collection.

Please note that any paper submitted is subject to the standard Article Processing Charge. Contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

The deadline for submitting manuscripts is 31 December 2024.

Guest Advisors

Manfredi Rizzo, University of Palermo, Italy

[email protected]

Prof. Rizzo is Professor of Internal Medicine at the School of Medicine, University of Palermo, Italy with a joint position as Head of the Unit of Diabetes and Cardiovascular Prevention at the University Hospital (Policlinic) of Palermo. He is also the Head of the Cardiometabolic Research Laboratory of the Department of Internal Medicine at the University of Palermo.

Dimitrios Patoulias, Aristotle University of Thessaloniki, Greece

[email protected]

Dimitrios Patoulias, MD, MSc, PhD, FRCP(Lond), FNEASO, FNSCOPE, is an Internal Medicine physician with special interest in Cardiometabolic Medicine. He has authored or co-authored >250 peer-reviewed articles indexed in PubMed database, mainly in the field of Cardiometabolic Medicine. His current h-index is 18.

View all papers in this article collection